Buy Or Sell Opportunity • Jun 01
Now 22% undervalued Over the last 90 days, the stock has risen 5.9% to €1.37. The fair value is estimated to be €1.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 10% over the last 3 years. Earnings per share has declined by 52%. Buy Or Sell Opportunity • May 13
Now 22% undervalued The stock has been flat over the last 90 days, currently trading at €1.33. The fair value is estimated to be €1.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 10.0% over the last 3 years. Earnings per share has declined by 52%. New Risk • May 12
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€19.4m market cap, or US$22.8m). Duyuru • May 07
BIO-UV Group S.A., Annual General Meeting, Jun 12, 2026 BIO-UV Group S.A., Annual General Meeting, Jun 12, 2026. Location: 850 avenue louis medard, lunel France New Risk • Apr 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€16.9m market cap, or US$19.5m). Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €1.54, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 19x in the Machinery industry in France. Total loss to shareholders of 66% over the past three years. Duyuru • May 10
BIO-UV Group S.A., Annual General Meeting, Jun 13, 2025 BIO-UV Group S.A., Annual General Meeting, Jun 13, 2025. Location: 850 avenue louis medard, lunel France Reported Earnings • May 05
Full year 2024 earnings released Full year 2024 results: Revenue: €39.2m (down 6.8% from FY 2023). Net income: €31.4k (down 75% from FY 2023). Profit margin: 0.1% (down from 0.3% in FY 2023). New Risk • Apr 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€22.7m market cap, or US$24.8m). New Risk • Apr 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€25.8m market cap, or US$27.9m). New Risk • Dec 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€19.7m market cap, or US$20.5m). New Risk • Jun 21
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (€22.4m market cap, or US$23.9m). New Risk • Jun 17
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.3% Last year net profit margin: 4.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (79% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (€20.6m market cap, or US$22.1m). Price Target Changed • May 31
Price target increased by 7.8% to €6.20 Up from €5.75, the current price target is provided by 1 analyst. New target price is 177% above last closing price of €2.24. Stock is down 43% over the past year. The company is forecast to post earnings per share of €0.41 for next year compared to €0.24 last year. Duyuru • May 25
BIO-UV Group S.A., Annual General Meeting, Jun 26, 2024 BIO-UV Group S.A., Annual General Meeting, Jun 26, 2024. Location: 850 avenue louis medard, lunel France New Risk • Apr 04
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€26.5m market cap, or US$28.8m). Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €2.88, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 7x in the Machinery industry in France. Total loss to shareholders of 51% over the past three years. New Risk • Oct 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€27.0m market cap, or US$28.6m). New Risk • Oct 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (€25.2m market cap, or US$26.6m). Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €2.49, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 8x in the Machinery industry in France. Total loss to shareholders of 57% over the past three years. Upcoming Dividend • Sep 20
Upcoming dividend of €0.06 per share at 1.1% yield Eligible shareholders must have bought the stock before 27 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 16% but the company is paying out more than the cash it is generating. Trailing yield: 1.1%. Lower than top quartile of French dividend payers (5.2%). In line with average of industry peers (1.2%). Major Estimate Revision • Jul 27
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €52.3m to €49.0m. EPS estimate also fell from €0.31 per share to €0.27 per share. Net income forecast to grow 53% next year vs 66% growth forecast for Machinery industry in France. Consensus price target down from €5.75 to €5.55. Share price fell 3.1% to €3.70 over the past week. Price Target Changed • Apr 06
Price target decreased by 12% to €5.75 Down from €6.55, the current price target is an average from 2 analysts. New target price is 30% above last closing price of €4.43. Stock is down 8.7% over the past year. The company is forecast to post earnings per share of €0.44 for next year compared to €0.067 last year. Board Change • Nov 16
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Head of Financial Information, COO & Director Laurent-Emmanuel Migeon is the most experienced director on the board, commencing their role in 2018. Independent Director Sylvie Roussel was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • May 02
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: €0.068 (vs €0.068 in FY 2020). Revenue: €34.6m (up 5.0% from FY 2020). Net income: €794.8k (up 36% from FY 2020). Profit margin: 2.3% (up from 1.8% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 55%, compared to a 27% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Head of Financial Information, COO & Director Laurent-Emmanuel Migeon is the most experienced director on the board, commencing their role in 2018. Independent Director Sylvie Roussel was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €4.15, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Machinery industry in France. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.70 per share. Reported Earnings • Sep 26
First half 2021 earnings released: EPS €0.057 (vs €0.015 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €17.2m (up 23% from 1H 2020). Net income: €588.3k (up €713.0k from 1H 2020). Profit margin: 3.4% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Price Target Changed • Jul 26
Price target decreased to €7.25 Down from €8.35, the current price target is an average from 2 analysts. New target price is 31% above last closing price of €5.54. Stock is down 9.2% over the past year. Is New 90 Day High Low • Mar 11
New 90-day low: €5.54 The company is down 9.0% from its price of €6.06 on 11 December 2020. The French market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.78 per share. Is New 90 Day High Low • Dec 28
New 90-day high: €6.70 The company is up 6.0% from its price of €6.32 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.40 per share. Is New 90 Day High Low • Oct 24
New 90-day low: €5.76 The company is down 9.0% from its price of €6.30 on 24 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Machinery industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.28 per share. Is New 90 Day High Low • Oct 01
New 90-day low: €5.88 The company is down 6.0% from its price of €6.26 on 03 July 2020. The French market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.76 per share. Reported Earnings • Sep 26
First half earnings released Over the last 12 months the company has reported total losses of €433.5k, with losses widening by 283% from the prior year. Total revenue was €25.9m over the last 12 months, up 55% from the prior year.